Literature DB >> 8866917

Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes.

U Christians1, G Schmidt, A Bader, A Lampen, R Schottmann, A Linck, K F Sewing.   

Abstract

1. Tacrolimus, an immunosuppressive macrolide, is metabolized by enzymes of the cytochrome P450 3A subfamily. In this study, 34 drugs were tested for their interactions with tacrolimus metabolism by human liver microsomes. 2. Fifteen drugs which inhibit the in vitro metabolism of tacrolimus were identified: bromocriptine, corticosterone, dexamethasone, ergotamine, erythromycin, ethinyloestradiol, josamycin, ketoconazole, miconazole, midazolam, nifedipine, omeprazole, tamoxifen, troleandomycin and verapamil.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8866917     DOI： 10.1111/j.1365-2125.1996.tb00181.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  18 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

2.  The influence of comedication on tacrolimus blood concentration in patients subjected to kidney transplantation: a retrospective study.

Authors:  Neven Vavic; Nemanja Rancic; Viktorija Dragojevic-Simic; Biljana Draskovic-Pavlovic; Dubravko Bokonjic; Ljiljana Ignjatovic; Momir Mikov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-12-20       Impact factor: 2.441

3.  Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients.

Authors:  Terry E Jones; Raymond G Morris
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Clinically significant drug interactions with agents specific for migraine attacks.

Authors:  M J Eadie
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

5.  Mechanistic Assessment of the Effect of Omeprazole on the In Vivo Pharmacokinetics of Itraconazole in Healthy Volunteers.

Authors:  Ahmad Y Abuhelwa; Stuart Mudge; Richard N Upton; David J R Foster
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-04       Impact factor: 2.441

Review 6.  Drug interactions with tacrolimus.

Authors:  Teun van Gelder
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 7.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients.

Authors:  Paraskevi F Katsakiori; Eirini P Papapetrou; Dimitrios S Goumenos; George C Nikiforidis; Christodoulos S Flordellis
Journal:  Ther Clin Risk Manag       Date:  2010-06-24       Impact factor: 2.423

9.  Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids.

Authors:  Dennis A Hesselink; Hien Ngyuen; Marike Wabbijn; Peter J H Smak Gregoor; Ewout W Steyerberg; Iza C van Riemsdijk; Willem Weimar; Teun van Gelder
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

10.  Brain concentrations of d-MDMA are increased after stress.

Authors:  Elizabeth Anne Johnson; James P O'Callaghan; Diane B Miller
Journal:  Psychopharmacology (Berl)       Date:  2004-01-20       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.